Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study is a prospective phase II, single arm mono-institutional study conducted in Queen
Mary Hospital (Hong Kong) assessing the efficacy and safety of TAS 102 in advanced or
metastatic pancreatic cancer patients.